Psyence Group Completes Stake Transfer to Psyence Biomedical
PsyLabs is an innovator that specializes in the cultivation and production of pharmaceutical-grade psychedelics directed at mental health and wellness applications. Recently, Psyence Group Inc. (CSE: PSYG) has made significant strides by closing its previously announced sale of an 11.13% interest in PsyLabs, transferring this stake to its affiliate, Psyence Biomedical Ltd (NASDAQ: PBM).
The arrangement marks a pivotal moment for the company, as Psyence Biomed will provide 2,000,000 shares of its common stock to Psyence Group as part of this acquisition.
PsyLabs: A Key Player in Psychedelic Research
PsyLabs has established itself as a crucial player in the development of active pharmaceutical ingredients (APIs) derived from psychedelics for research, clinical trials, and drug development. The strategic partnership between Psyence Biomed and PsyLabs allows the latter to supply pharmaceutical-grade psilocybin to be utilized in clinical evaluations aimed at addressing Alcohol Use Disorder (AUD) and other substance-related issues.
Dr. Neil Maresky, CEO of Psyence Biomed, expressed enthusiasm regarding this acquisition, stating that it enhances their standing as one of the few companies globally engaged in the vertical integration of psychedelic medical products.
Debt-for-Equity Swap Agreement Details
The transaction was further complemented by a debt-for-equity swap agreement between Psyence Group and Psyence Biomed. In this arrangement, Psyence Biomed will issue 845,394 common shares at a value of US$0.50 per share. This exchange is designed to settle a promissory note due to Psyence Group, originally issued when Psyence Biomed went public on NASDAQ.
If the average trading price of Psyence Biomed shares falls below US$0.50 by January 15, 2025, they are required to provide additional payments to cover the difference, ensuring a level of financial security for Psyence Group.
About PsyLabs and Its Operations
PsyLabs is federally licensed to cultivate and export a range of psychedelic compounds, including psilocin and DMT, targeting the legal medical and research industries. Utilizing proprietary extraction and purification methods, PsyLabs has achieved unprecedented levels of purified natural psilocybin. Their goal is to achieve full-scale commercial production alongside meeting regulatory standards.
They plan to collaborate with the largest UK-owned contract manufacturing organization to realize this ambition.
Psyence Group's Commitment to Psychedelic Science
Psyence Group is committed to the advancement of life science biotechnology focused on natural psychedelics. Their mission aligns with fostering innovative solutions for psychological trauma treatment and other mental health challenges.
This integration and growth strategy through the acquisition and partnerships signify Psyence Group's proactive approach toward enhancing its capabilities and market presence. The effort reflects a broader interest in the potential of psychedelics for therapeutic applications based on scientific research.
Contact Information
General Inquiries for Psyence Group:
Email: ir@psyence.com
Phone: +1 416-477-1708
Media Inquiries:
Email: media@psyence.com
Frequently Asked Questions
What was the purpose of Psyence Group's stake transfer?
The stake transfer aimed to consolidate resources within Psyence Biomed and enhance growth opportunities in psychedelic therapeutics.
What is PsyLabs' primary focus?
PsyLabs focuses on developing and producing active pharmaceutical ingredients derived from psychedelics for clinical and research purposes.
How does the debt-for-equity swap benefit Psyence Group?
This swap allows Psyence Group to settle a debt while acquiring common shares, potentially increasing their value and participation in future successes of Psyence Biomed.
Who is driving the initiatives at Psyence Biomed?
Dr. Neil Maresky serves as the CEO of Psyence Biomed, leading efforts in the development and commercialization of psychedelic medicines.
How can interested parties learn more about Psyence Group?
To learn more, interested individuals can visit **www.psyence.com** for comprehensive information on products and initiatives.
